Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2003;326:1078-1079 (17 May), doi:10.1136/bmj.326.7398.1078
Adrian Plunkett, senior house officer1, J A Hulse, consultant paediatrician1, B Mishra, consultant cardiologist2, J Gill, consultant cardiologist3
1 Department of Paediatrics, Maidstone Hospital, Maidstone ME16 9QQ, 2 Department of Cardiology, Maidstone Hospital, 3 Department of Cardiology, St Thomas's Hospital, London SE1 7EH
Correspondence to: A Plunkett adrianplunkett{at}doctors.org.uk
Brugada syndrome is an inherited cardiac disease causing ventricular tachyarrhythmias in patients with structurally normal hearts.1 Since its first description in 1992, the number of cases reported worldwide has grown substantially, and it is thought to account for many cases of unexpected sudden death.
The syndrome is characterised by a history of syncope or cardiac arrest and a characteristic electrocardiographic pattern: right bundle branch block and ST segment elevation in V1 to V3. Most cases are inherited as an autosomal dominant trait, explaining a strong family history of syncope or sudden death.2 Some patients have normal resting electrocardiographic appearances but the classic changes can be induced by giving ajmaline, an antiarrhythmic drug.3
Examination showed no abnormality, but her resting electrocardiogram showed partial right bundle branch block (fig 1). Twenty four hour cardiac monitoring and echocardiography gave normal results. However, a patient activated electrocardiograph showed ventricular tachycardia during a symptomatic spell. An electrophysiological study showed ventricular tachycardia during ventricular stimulation. She had magnetic resonance imaging of the heart to rule out right ventricular dysplasia, and this showed no abnormality.
|
In view of the electrocardiogram and the recurrent ventricular tachycardia, in a structurally normal heart, a diagnosis of Brugada syndrome was made. A cardioverter defibrillator was implanted to prevent any life threatening arrhythmias. Since then she has remained well.
After her daughter had Brugada syndrome diagnosed, she was referred to the cardiologist who had been looking after her daughter. Her resting electrocardiogram appeared normal, but an ajmaline test provoked changes consistent with Brugada syndrome (fig 2). She had a cardioverter defibrillator inserted and has since been free of symptoms.
|
He presented to hospital aged 6 years after an episode of collapse associated with cyanosis and unconsciousness. His electrocardiogram showed partial right bundle branch block, which was attributed to his previous cardiac surgery. Results of 24 hour cardiac monitoring and electroencephalography were normal.
He continued to have dizzy spells and collapses, culminating in a severe episode at school, three months after his mother had Brugada syndrome diagnosed. The episode was witnessed by his teacher, who reported that his pulse rate was extremely rapid during the attack. Subsequent investigations confirmed that he had Brugada syndrome, and he has remained free of symptoms since the insertion of a cardioverter defibrillator.
Diagnosing Brugada syndrome is not straight-forward as it exists in many forms. The syndrome is inherited as an autosomal dominant trait, but expression variesfor example, the typical electrocardiographic pattern is often absent or transitory.5 The syndrome is most common in men of South East Asian origin, but it has been described in many different age groups and ethnic origins.5
Our report shows the difficulty in diagnosing Brugada syndrome in atypical cases. Case 2 had symptoms but normal resting electrocardiographic appearances. Diagnosis in such patients depends on unmasking concealed conduction abnormalities by giving intravenous antiarrhythmic drugs such as ajmaline. This test is useful because symptomatic patients are at risk of sudden death if left untreated.6
Case 2 also illustrates the difficulty in distinguishing cardiac causes of loss of consciousness from neurological causes. Investigations in all cases of unexplained syncope should include resting and 24 hour electrocardiography. However, normal results do not exclude Brugada syndrome, and if the patient is at risk an ajmaline test should be considered.
Diagnosis is further complicated by unrelated conditions such as right ventricular dysplasia, in which the electrocardiogram may show the typical Brugada-like pattern and the patient is prone to sudden arrhythmic death.7 Structural heart disease must therefore be excluded before diagnosing Brugada syndrome.
Identification of a genetic abnormality is helpful in distinguishing Brugada syndrome. Furthermore, identification of a recognised mutation will facilitate screening of relatives. The genetic defect is a mutated cardiac sodium channel gene (SCN5A) on chromosome 3.8 The mutant sodium channel shortens the cardiac action potential, making parts of the cardiac tissue vulnerable to re-entry circuits. There are several recognised mutations causing Brugada syndrome, but in many cases a recognised mutation is not found. Such genetic heterogeneity may explain the heterogeneity of expression between individuals.
The prognosis for patients with Brugada syndrome is poor unless they are treated. Mortality is thought to be up to 10% a year.5 Drug treatment is not effective, but an implantable cardioverter defibrillator has been shown to prevent sudden death.3
Contributors: AP wrote the paper. JAH and BM supervised and revised the paper. JG contributed to the diagnosis and management of the cases. JAH is the guarantor.
Competing interests: None declared.
Read all Rapid Responses
What can you learn from this BMJ paper? Read Leanne Tite's Paper+